Israel to offer AstraZeneca's Evusheld to immunocompromised people – Reuters

Israel to offer AstraZeneca's Evusheld to immunocompromised people – Reuters

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid
JERUSALEM, Feb 15 (Reuters) – Israel will start offering AstraZeneca’s (AZN.L) antibody cocktail Evusheld, which is used to prevent COVID-19, to people with compromised immune systems who did not get a sufficient antibody boost from vaccines.
Evusheld has been approved by the U.S. Food and Drug Administration and has proven to be 83% effective in preventing serious illness and death from COVID-19, the Health Ministry said on Tuesday.
It is not a treatment for those already sick or a prevention for those already exposed to the virus, it said.
Evusheld will be made available for people 12 and older who weigh more than 40 kg (88 lb), according to a Health Ministry statement.
It said Evusheld will "be given regardless of past recovery from COVID-19 or receiving previous coronavirus vaccine doses, provided that two weeks have passed since getting the vaccine."
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source


Leave a Reply

Your email address will not be published.